The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Clinical trial NCT05281068 · UNKNOWN
Trial details
- NCT number
- NCT05281068
- Sponsor
- Peking University People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-01
- Primary completion
- 2023-09-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.